Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.52 |
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993390 | 0.91 | ESR2 (0.47) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL13368345 | 0.91 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL16576984 | 0.89 | ESR2 (0.69) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL13615716 | 0.89 | ESR2 (0.62) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1692149 | 0.89 | HAO1 (0.46) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9284476 | 0.86 | ESR2 (0.50) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9284474 | 0.86 | ESR2 (0.50) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL12733063 | 0.85 | KCNH2 (0.41) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL8284802 | 0.85 | SLC18A3 (0.55) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL14048316 | 0.84 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250092004-A1 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-20 | — | — | US | disclosed |
| EP-4464697-A1 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| CN-118574816-A | Preparation method of intermediate for synthesizing SGLT inhibitor | 株式会社大熊制药 | 2024-08-30 | — | — | CN | disclosed |
| CN-1503793-A | N-substituted non-aryl-heterocyclic NMDA/NR2B antagonists | — | 2004-06-09 | — | — | CN | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2003-06-26 | — | — | US | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | ESR2 1008/4885ESR1 3097/4885CYP3A4 2899/4885 |
| US-20250092004-A1 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | SLC5A1, SLC5A2, SUGT1 | ESR2 4136/4885ESR1 4135/4885CYP3A4 1183/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | ESR2 2071/4885ESR1 2970/4885CYP3A4 4346/4885 |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | GRIN1, GRIN2B, GRIN2A | ESR2 957/4885ESR1 2549/4885CYP3A4 3795/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | ESR2 3884/4885ESR1 4160/4885CYP3A4 1380/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | ESR2 773/4885ESR1 1976/4885CYP3A4 3416/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | ESR2 671/4885ESR1 1453/4885CYP3A4 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.